COMMUNIQUÉS West-GlobeNewswire

BiomX Appoints IDF Colonel (res.) Roy Timor-Rousso as Chief Business Officer to Strengthen Defense & Security Operations
27/05/2026
Roy brings defense leadership, digital infrastructure, and large scale commercialization experience as BiomX advances its defense and security transition NETANYA, Israel, May 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. ( [...]
Medicana Health Group Opens Medicana Longevity Center In Istanbul, Led By Prof. Dr. Osman Müftüoğlu
27/05/2026
The new “Longevity and Age-Related Diseases” outpatient clinic at Medicana Zincirlikuyu Hospital introduces a holistic approach focused not only on longer life, but on stronger, healthier aging Photo via FL Comms: The [...]
Therini Bio Doses First Patients in Phase 1b Trial of Novel Anti-Inflammatory Therapy, THN391, for Diabetic Macular Edema
27/05/2026
Company also advances fibrin/VEGF bispecific antibody THN622, a potential new standard of care for retinal neurodegeneration SACRAMENTO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Therini Bio, Inc., a clinical-stage [...]
Simple’s Avo™ Named “Best Virtual Health Coach” in MedTech Breakthrough Awards Program
27/05/2026
Landmark 10th Annual Awards Program Recognizes the Most Innovative Digital Health and Medical Technology Solutions Worldwide LOS ANGELES, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- MedTech Breakthrough , an independent [...]
UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine
27/05/2026
Conexeu to leverage WFIRM's advanced tissue-organ bioprinting infrastructure to evaluate the durability, integration, and resorbability of proprietary CXU™ 3D-printed matrix technology RENO, Nev., May 27, 2026 (GLOBE [...]
Zealand Pharma to participate in the Jefferies Global Healthcare Conference
27/05/2026
Press release – No. 11 / 2026 Zealand Pharma to participate in the Jefferies Global Healthcare Conference Copenhagen, Denmark, May 27, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company [...]
Agomab Announces Results of Annual General Meeting
27/05/2026
Antwerp, Belgium, May 27, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual General Meeting (AGM [...]
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026
27/05/2026
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, [...]
InnoCare Announces Approval of Orelabrutinib in Australia
27/05/2026
BEIJING, May 27, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that orelabrutinib (HIBRUKA ® ) has [...]
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
27/05/2026
APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H 2026 Zumilokibart [...]
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
27/05/2026
Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt Combined with company's current total cash of $1.3 [...]
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
27/05/2026
PRINCETON, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the [...]
MitoRx Therapeutics to present new preclinical data on MTRX31, its novel mitochondrial-targeted small molecule at the American Diabetes Association’s 2026 Scientific Sessions
27/05/2026
Poster to be presented at ADA 2026 on weight loss induced by MTRX31 in an industry-standard preclinical model of obesity MitoRx Chief Scientific Officer Xavier Jacq to also participate in panel and deliver corporate [...]
Sharps Technology Becomes SkyAI, Inc. with New Ticker Symbol “SKYA”; Establishing Category-defining Agentic Finance Platform Serving Global South
27/05/2026
Rebrand to SkyAI, Inc. to reflect evolution of the business to build a global agentic finance platform Opened operational headquarters in Hong Kong, a global hub for financial technology innovation and a base for [...]
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
27/05/2026
Deployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to the delivery of Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and other neurological [...]
Korro to Present at the 2026 Jefferies Global Healthcare Conference
27/05/2026
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA ® ) platform to develop a new [...]
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
27/05/2026
RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio [...]
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
27/05/2026
WATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
27/05/2026
Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-CD40L monoclonal antibody for the prevention of kidney transplant rejection Phase 2 investigator-initiated study in [...]

Pages